Adaptive SBRT to para‑aortic and iliac lymph nodes to help prostate cancer responses last longer.
Official title: A Phase I, Prospective, Single-Arm Feasibility Study: Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response (EASY)
Run by University Health Network, Toronto · NCT06831032 · Data updated 2026-11-12
This study will try CT-guided, online adaptive SBRT to the tumor and nearby at-risk lymph nodes to see if men with oligorecurrent para‑aortic or common iliac nodal prostate cancer get longer-lasting control.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 26 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | April 13, 2026 |
| Main results expected | April 13, 2029 |
| Study ends | April 13, 2029 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT06831032 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men with prostate adenocarcinoma who have controlled primary disease and limited (≤10) oligorecurrent para‑aortic and/or common iliac lymph node metastases on PSMA PET or CT/MRI, with ECOG 0–2 and no prior radiotherapy to those nodal regions.
✕Probably not a fit
Patients with more extensive nodal or distant metastatic disease, prior radiation to the para‑aortic/iliac nodal echelon, significant comorbidities, or contraindications to radiation are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm feasibility trial enrolling men with histologically confirmed prostate adenocarcinoma who have controlled local disease and oligorecurrent para‑aortic and/or common iliac nodal metastases. Eligible patients (≤10 involved nodes within the specified para‑aortic/common iliac regions, ECOG 0–2) will undergo CT-guided online adaptive stereotactic body radiotherapy to visible nodal tumors plus elective SBRT to adjacent at-risk nodal regions. Patients with prior radiotherapy to the same nodal echelon or contraindications to radiation are excluded. Outcomes will focus on feasibility, safety, and durability of nodal control following this elective adaptive SBRT approach.
Why it matters
Potential benefit: If successful, this approach could extend the duration of nodal disease control and delay the need for systemic therapies, potentially preserving quality of life.
How similar studies have gone: Metastasis-directed SBRT for oligorecurrent prostate cancer has shown promise in delaying progression in other trials, but elective, CT-guided online adaptive SBRT to para‑aortic/iliac nodal regions is a newer and less-tested strategy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed prostate adenocarcinoma. 2. Oligorecurrent para-aortic +/- common iliac nodal disease planned for SBRT. 3. ≤10 involved para-aortic (defined as between L1/L2 interface and L4/L5 interface) +/- common iliac LN on PSMA PET imaging. 4. ECOG performance status 0-2. Exclusion Criteria: 1. Prior radiotherapy to the nodal echelon (PA +/- common iliac). 2. Active secondary malignancy, except for adequately treated non-melanoma skin cancer. 3. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study. 4. Contraindication to radiation.
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Andrew McPartlin, MD
- Email: andrew.mcpartlin@uhn.ca
- Phone: 416-946-4501
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer
This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.
-
Lower-dose radiation to parts of the prostate for some men with prostate cancer
This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.
-
Next-generation SABR for prostate cancer across Ireland
This test uses focused high-dose stereotactic radiotherapy (SABR) with urethra-sparing, a rectal spacer, and nerve preservation for men with low-, intermediate-, or selected high-risk prostate cancer to try to control the tumor while reducing side effects.
-
Focal HDR-Brachytherapy for Prostate Cancer
This trial tests using targeted high-dose-rate brachytherapy to treat prostate cancer patients and see if it provides local control with fewer side effects.
-
Shorter androgen deprivation in combination with radiation for high-risk prostate cancer
Doctors are testing whether 6 months of hormone therapy with radiation works as well as 18 months, for men with high-risk prostate cancer.
-
PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance
This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.